JEFFREY KLUNZINGER

Jeffrey Klunzinger is a distinguished figure in the venture capital landscape, currently serving as the Managing Partner at OS Fund. In this crucial role, he leads the firm's investment strategy, focusing on identifying and nurturing companies at the forefront of scientific and technological innovation. OS Fund is renowned for its commitment to 'deep tech' or 'frontier tech,' backing ventures that are not merely incremental but truly transformative.

Under Klunzinger's leadership, OS Fund targets companies that are developing foundational technologies with the potential to reinvent industries and address significant global challenges. His investment focus areas are broad yet specific, encompassing artificial intelligence, biotechnology, advanced materials, computational biology, space exploration, and new energy solutions. He seeks out visionary founders who are building proprietary technologies and scientific breakthroughs, often at the intersection of multiple disciplines. The fund's philosophy, guided by Klunzinger, emphasizes long-term partnerships with entrepreneurs who are tackling complex problems with innovative solutions.

Klunzinger's career background is marked by a strong foundation in both finance and technology. Before co-founding OS Fund, he held a significant position as a Partner at Founders Fund, another prominent venture capital firm known for its early investments in groundbreaking companies. Prior to his tenure at Founders Fund, Klunzinger was instrumental in the growth of Palantir Technologies, where he served as Vice President and Head of Business Development. His experience at Palantir provided him with deep insights into scaling innovative technology companies and understanding complex data challenges. His professional journey began in investment banking at Goldman Sachs, where he honed his financial acumen and strategic thinking. This diverse background equips him with a unique perspective, enabling him to evaluate both the scientific merit and commercial viability of nascent technologies.

While specific investments are often attributed to the fund, Jeffrey Klunzinger's strategic direction has been integral to OS Fund's impressive portfolio. Notable companies within the OS Fund portfolio, reflecting the firm's deep tech focus, include Synthego (genome engineering), Recursion Pharmaceuticals (AI-driven drug discovery), Rigetti Computing (quantum computing), Ginkgo Bioworks (synthetic biology), and Atom Computing (quantum computing). These investments underscore Klunzinger's commitment to supporting companies that are pushing the boundaries of what's possible and driving the next wave of scientific and technological progress. His work at OS Fund continues to shape the future by empowering the innovators who are building it.